JP2022095908A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2022095908A5 JP2022095908A5 JP2022067540A JP2022067540A JP2022095908A5 JP 2022095908 A5 JP2022095908 A5 JP 2022095908A5 JP 2022067540 A JP2022067540 A JP 2022067540A JP 2022067540 A JP2022067540 A JP 2022067540A JP 2022095908 A5 JP2022095908 A5 JP 2022095908A5
- Authority
- JP
- Japan
- Prior art keywords
- therapeutic agent
- cancer
- her2
- antibody
- agent according
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000003814 drug Substances 0.000 claims 37
- 229940124597 therapeutic agent Drugs 0.000 claims 36
- 206010028980 Neoplasm Diseases 0.000 claims 14
- 201000011510 cancer Diseases 0.000 claims 14
- 239000000611 antibody drug conjugate Substances 0.000 claims 11
- 229940049595 antibody-drug conjugate Drugs 0.000 claims 11
- 101001012157 Homo sapiens Receptor tyrosine-protein kinase erbB-2 Proteins 0.000 claims 10
- 102100030086 Receptor tyrosine-protein kinase erbB-2 Human genes 0.000 claims 10
- 229940043275 anti-HER2 drug Drugs 0.000 claims 6
- 125000003275 alpha amino acid group Chemical group 0.000 claims 4
- 239000002246 antineoplastic agent Substances 0.000 claims 4
- 229940041181 antineoplastic drug Drugs 0.000 claims 4
- 229960000575 trastuzumab Drugs 0.000 claims 4
- 229960001612 trastuzumab emtansine Drugs 0.000 claims 4
- 208000005718 Stomach Neoplasms Diseases 0.000 claims 3
- 206010017758 gastric cancer Diseases 0.000 claims 3
- 238000012151 immunohistochemical method Methods 0.000 claims 3
- 201000011549 stomach cancer Diseases 0.000 claims 3
- 206010006187 Breast cancer Diseases 0.000 claims 2
- 208000026310 Breast neoplasm Diseases 0.000 claims 2
- 206010009944 Colon cancer Diseases 0.000 claims 2
- AOJJSUZBOXZQNB-TZSSRYMLSA-N Doxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-TZSSRYMLSA-N 0.000 claims 2
- 239000002136 L01XE07 - Lapatinib Substances 0.000 claims 2
- NWIBSHFKIJFRCO-WUDYKRTCSA-N Mytomycin Chemical compound C1N2C(C(C(C)=C(N)C3=O)=O)=C3[C@@H](COC(N)=O)[C@@]2(OC)[C@@H]2[C@H]1N2 NWIBSHFKIJFRCO-WUDYKRTCSA-N 0.000 claims 2
- 208000004337 Salivary Gland Neoplasms Diseases 0.000 claims 2
- 206010061934 Salivary gland cancer Diseases 0.000 claims 2
- 150000001413 amino acids Chemical class 0.000 claims 2
- 208000029742 colonic neoplasm Diseases 0.000 claims 2
- 229940000425 combination drug Drugs 0.000 claims 2
- 201000007492 gastroesophageal junction adenocarcinoma Diseases 0.000 claims 2
- 238000007901 in situ hybridization Methods 0.000 claims 2
- 229960004768 irinotecan Drugs 0.000 claims 2
- UWKQSNNFCGGAFS-XIFFEERXSA-N irinotecan Chemical compound C1=C2C(CC)=C3CN(C(C4=C([C@@](C(=O)OC4)(O)CC)C=4)=O)C=4C3=NC2=CC=C1OC(=O)N(CC1)CCC1N1CCCCC1 UWKQSNNFCGGAFS-XIFFEERXSA-N 0.000 claims 2
- 229960004891 lapatinib Drugs 0.000 claims 2
- BCFGMOOMADDAQU-UHFFFAOYSA-N lapatinib Chemical compound O1C(CNCCS(=O)(=O)C)=CC=C1C1=CC=C(N=CN=C2NC=3C=C(Cl)C(OCC=4C=C(F)C=CC=4)=CC=3)C2=C1 BCFGMOOMADDAQU-UHFFFAOYSA-N 0.000 claims 2
- 125000005647 linker group Chemical group 0.000 claims 2
- 229910052757 nitrogen Inorganic materials 0.000 claims 2
- 125000004433 nitrogen atom Chemical group N* 0.000 claims 2
- 208000002154 non-small cell lung carcinoma Diseases 0.000 claims 2
- 229960002087 pertuzumab Drugs 0.000 claims 2
- 208000029729 tumor suppressor gene on chromosome 11 Diseases 0.000 claims 2
- AOJJSUZBOXZQNB-VTZDEGQISA-N 4'-epidoxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-VTZDEGQISA-N 0.000 claims 1
- RYYCJUAHISIHTL-UHFFFAOYSA-N 5-azaorotic acid Chemical compound OC(=O)C1=NC(=O)NC(=O)N1 RYYCJUAHISIHTL-UHFFFAOYSA-N 0.000 claims 1
- 206010004593 Bile duct cancer Diseases 0.000 claims 1
- GAGWJHPBXLXJQN-UORFTKCHSA-N Capecitabine Chemical compound C1=C(F)C(NC(=O)OCCCCC)=NC(=O)N1[C@H]1[C@H](O)[C@H](O)[C@@H](C)O1 GAGWJHPBXLXJQN-UORFTKCHSA-N 0.000 claims 1
- GAGWJHPBXLXJQN-UHFFFAOYSA-N Capecitabine Natural products C1=C(F)C(NC(=O)OCCCCC)=NC(=O)N1C1C(O)C(O)C(C)O1 GAGWJHPBXLXJQN-UHFFFAOYSA-N 0.000 claims 1
- CMSMOCZEIVJLDB-UHFFFAOYSA-N Cyclophosphamide Chemical compound ClCCN(CCCl)P1(=O)NCCCO1 CMSMOCZEIVJLDB-UHFFFAOYSA-N 0.000 claims 1
- HTIJFSOGRVMCQR-UHFFFAOYSA-N Epirubicin Natural products COc1cccc2C(=O)c3c(O)c4CC(O)(CC(OC5CC(N)C(=O)C(C)O5)c4c(O)c3C(=O)c12)C(=O)CO HTIJFSOGRVMCQR-UHFFFAOYSA-N 0.000 claims 1
- 208000000461 Esophageal Neoplasms Diseases 0.000 claims 1
- GHASVSINZRGABV-UHFFFAOYSA-N Fluorouracil Chemical compound FC1=CNC(=O)NC1=O GHASVSINZRGABV-UHFFFAOYSA-N 0.000 claims 1
- ZPLQIPFOCGIIHV-UHFFFAOYSA-N Gimeracil Chemical compound OC1=CC(=O)C(Cl)=CN1 ZPLQIPFOCGIIHV-UHFFFAOYSA-N 0.000 claims 1
- FBOZXECLQNJBKD-ZDUSSCGKSA-N L-methotrexate Chemical compound C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 FBOZXECLQNJBKD-ZDUSSCGKSA-N 0.000 claims 1
- 239000005411 L01XE02 - Gefitinib Substances 0.000 claims 1
- 239000005551 L01XE03 - Erlotinib Substances 0.000 claims 1
- 239000002138 L01XE21 - Regorafenib Substances 0.000 claims 1
- ZDZOTLJHXYCWBA-VCVYQWHSSA-N N-debenzoyl-N-(tert-butoxycarbonyl)-10-deacetyltaxol Chemical compound O([C@H]1[C@H]2[C@@](C([C@H](O)C3=C(C)[C@@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)C=4C=CC=CC=4)C[C@]1(O)C3(C)C)=O)(C)[C@@H](O)C[C@H]1OC[C@]12OC(=O)C)C(=O)C1=CC=CC=C1 ZDZOTLJHXYCWBA-VCVYQWHSSA-N 0.000 claims 1
- 206010030155 Oesophageal carcinoma Diseases 0.000 claims 1
- 208000010191 Osteitis Deformans Diseases 0.000 claims 1
- 206010033128 Ovarian cancer Diseases 0.000 claims 1
- 206010061535 Ovarian neoplasm Diseases 0.000 claims 1
- 229930012538 Paclitaxel Natural products 0.000 claims 1
- 208000027868 Paget disease Diseases 0.000 claims 1
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims 1
- 206010038111 Recurrent cancer Diseases 0.000 claims 1
- 229960001686 afatinib Drugs 0.000 claims 1
- ULXXDDBFHOBEHA-CWDCEQMOSA-N afatinib Chemical compound N1=CN=C2C=C(O[C@@H]3COCC3)C(NC(=O)/C=C/CN(C)C)=CC2=C1NC1=CC=C(F)C(Cl)=C1 ULXXDDBFHOBEHA-CWDCEQMOSA-N 0.000 claims 1
- 125000003277 amino group Chemical group 0.000 claims 1
- 229960000397 bevacizumab Drugs 0.000 claims 1
- 208000026900 bile duct neoplasm Diseases 0.000 claims 1
- 229960004117 capecitabine Drugs 0.000 claims 1
- 229960004562 carboplatin Drugs 0.000 claims 1
- 190000008236 carboplatin Chemical compound 0.000 claims 1
- 208000011892 carcinosarcoma of the corpus uteri Diseases 0.000 claims 1
- 229960005395 cetuximab Drugs 0.000 claims 1
- 208000006990 cholangiocarcinoma Diseases 0.000 claims 1
- 229960004316 cisplatin Drugs 0.000 claims 1
- DQLATGHUWYMOKM-UHFFFAOYSA-L cisplatin Chemical compound N[Pt](N)(Cl)Cl DQLATGHUWYMOKM-UHFFFAOYSA-L 0.000 claims 1
- 229960004397 cyclophosphamide Drugs 0.000 claims 1
- 229960003668 docetaxel Drugs 0.000 claims 1
- 229960004679 doxorubicin Drugs 0.000 claims 1
- 229940079593 drug Drugs 0.000 claims 1
- 229960001904 epirubicin Drugs 0.000 claims 1
- 229960001433 erlotinib Drugs 0.000 claims 1
- AAKJLRGGTJKAMG-UHFFFAOYSA-N erlotinib Chemical compound C=12C=C(OCCOC)C(OCCOC)=CC2=NC=NC=1NC1=CC=CC(C#C)=C1 AAKJLRGGTJKAMG-UHFFFAOYSA-N 0.000 claims 1
- 201000004101 esophageal cancer Diseases 0.000 claims 1
- 229960002949 fluorouracil Drugs 0.000 claims 1
- 238000009472 formulation Methods 0.000 claims 1
- 229960002584 gefitinib Drugs 0.000 claims 1
- XGALLCVXEZPNRQ-UHFFFAOYSA-N gefitinib Chemical compound C=12C=C(OCCCN3CCOCC3)C(OC)=CC2=NC=NC=1NC1=CC=C(F)C(Cl)=C1 XGALLCVXEZPNRQ-UHFFFAOYSA-N 0.000 claims 1
- 229960005277 gemcitabine Drugs 0.000 claims 1
- SDUQYLNIPVEERB-QPPQHZFASA-N gemcitabine Chemical compound O=C1N=C(N)C=CN1[C@H]1C(F)(F)[C@H](O)[C@@H](CO)O1 SDUQYLNIPVEERB-QPPQHZFASA-N 0.000 claims 1
- 229950009822 gimeracil Drugs 0.000 claims 1
- 238000003364 immunohistochemistry Methods 0.000 claims 1
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims 1
- 208000027202 mammary Paget disease Diseases 0.000 claims 1
- 238000000034 method Methods 0.000 claims 1
- 229960000485 methotrexate Drugs 0.000 claims 1
- 125000001570 methylene group Chemical group [H]C([H])([*:1])[*:2] 0.000 claims 1
- 229960004857 mitomycin Drugs 0.000 claims 1
- 239000000203 mixture Substances 0.000 claims 1
- 229950000193 oteracil Drugs 0.000 claims 1
- 229960001756 oxaliplatin Drugs 0.000 claims 1
- DWAFYCQODLXJNR-BNTLRKBRSA-L oxaliplatin Chemical compound O1C(=O)C(=O)O[Pt]11N[C@@H]2CCCC[C@H]2N1 DWAFYCQODLXJNR-BNTLRKBRSA-L 0.000 claims 1
- 229960001592 paclitaxel Drugs 0.000 claims 1
- 201000002528 pancreatic cancer Diseases 0.000 claims 1
- 208000008443 pancreatic carcinoma Diseases 0.000 claims 1
- 229960001972 panitumumab Drugs 0.000 claims 1
- 229960005079 pemetrexed Drugs 0.000 claims 1
- QOFFJEBXNKRSPX-ZDUSSCGKSA-N pemetrexed Chemical compound C1=N[C]2NC(N)=NC(=O)C2=C1CCC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 QOFFJEBXNKRSPX-ZDUSSCGKSA-N 0.000 claims 1
- 229960002633 ramucirumab Drugs 0.000 claims 1
- 229960004836 regorafenib Drugs 0.000 claims 1
- FNHKPVJBJVTLMP-UHFFFAOYSA-N regorafenib Chemical compound C1=NC(C(=O)NC)=CC(OC=2C=C(F)C(NC(=O)NC=3C=C(C(Cl)=CC=3)C(F)(F)F)=CC=2)=C1 FNHKPVJBJVTLMP-UHFFFAOYSA-N 0.000 claims 1
- RCINICONZNJXQF-MZXODVADSA-N taxol Chemical compound O([C@@H]1[C@@]2(C[C@@H](C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3([C@H]21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-MZXODVADSA-N 0.000 claims 1
- 229960001674 tegafur Drugs 0.000 claims 1
- WFWLQNSHRPWKFK-ZCFIWIBFSA-N tegafur Chemical compound O=C1NC(=O)C(F)=CN1[C@@H]1OCCC1 WFWLQNSHRPWKFK-ZCFIWIBFSA-N 0.000 claims 1
- QQHMKNYGKVVGCZ-UHFFFAOYSA-N tipiracil Chemical compound N1C(=O)NC(=O)C(Cl)=C1CN1C(=N)CCC1 QQHMKNYGKVVGCZ-UHFFFAOYSA-N 0.000 claims 1
- 229960002952 tipiracil Drugs 0.000 claims 1
- 229960003962 trifluridine Drugs 0.000 claims 1
- VSQQQLOSPVPRAZ-RRKCRQDMSA-N trifluridine Chemical compound C1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C(C(F)(F)F)=C1 VSQQQLOSPVPRAZ-RRKCRQDMSA-N 0.000 claims 1
- 201000005290 uterine carcinosarcoma Diseases 0.000 claims 1
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2024016749A JP2024054226A (ja) | 2016-10-07 | 2024-02-07 | 抗ｈｅｒ２抗体－薬物コンジュゲート投与による耐性癌の治療 |
Applications Claiming Priority (8)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2016199341 | 2016-10-07 | ||
| JP2016199341 | 2016-10-07 | ||
| JP2017097589 | 2017-05-16 | ||
| JP2017097589 | 2017-05-16 | ||
| JP2017172814 | 2017-09-08 | ||
| JP2017172814 | 2017-09-08 | ||
| PCT/JP2017/036215 WO2018066626A1 (ja) | 2016-10-07 | 2017-10-05 | 抗ｈｅｒ２抗体－薬物コンジュゲート投与による耐性癌の治療 |
| JP2018543951A JPWO2018066626A1 (ja) | 2016-10-07 | 2017-10-05 | 抗ｈｅｒ２抗体−薬物コンジュゲート投与による耐性癌の治療 |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018543951A Division JPWO2018066626A1 (ja) | 2016-10-07 | 2017-10-05 | 抗ｈｅｒ２抗体−薬物コンジュゲート投与による耐性癌の治療 |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024016749A Division JP2024054226A (ja) | 2016-10-07 | 2024-02-07 | 抗ｈｅｒ２抗体－薬物コンジュゲート投与による耐性癌の治療 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2022095908A JP2022095908A (ja) | 2022-06-28 |
| JP2022095908A5 true JP2022095908A5 (enExample) | 2023-03-08 |
Family
ID=61831486
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018543951A Pending JPWO2018066626A1 (ja) | 2016-10-07 | 2017-10-05 | 抗ｈｅｒ２抗体−薬物コンジュゲート投与による耐性癌の治療 |
| JP2022067540A Pending JP2022095908A (ja) | 2016-10-07 | 2022-04-15 | 抗ｈｅｒ２抗体－薬物コンジュゲート投与による耐性癌の治療 |
| JP2024016749A Withdrawn JP2024054226A (ja) | 2016-10-07 | 2024-02-07 | 抗ｈｅｒ２抗体－薬物コンジュゲート投与による耐性癌の治療 |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018543951A Pending JPWO2018066626A1 (ja) | 2016-10-07 | 2017-10-05 | 抗ｈｅｒ２抗体−薬物コンジュゲート投与による耐性癌の治療 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024016749A Withdrawn JP2024054226A (ja) | 2016-10-07 | 2024-02-07 | 抗ｈｅｒ２抗体－薬物コンジュゲート投与による耐性癌の治療 |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US20190330368A1 (enExample) |
| EP (1) | EP3524267A4 (enExample) |
| JP (3) | JPWO2018066626A1 (enExample) |
| KR (2) | KR20230158641A (enExample) |
| CN (1) | CN109789211A (enExample) |
| AU (2) | AU2017341000B2 (enExample) |
| BR (1) | BR112019005247A2 (enExample) |
| CA (1) | CA3036941C (enExample) |
| SG (1) | SG10201912173RA (enExample) |
| TW (2) | TWI868465B (enExample) |
| WO (1) | WO2018066626A1 (enExample) |
Families Citing this family (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3673918A4 (en) * | 2017-08-23 | 2021-05-19 | Daiichi Sankyo Company, Limited | PREPARATION OF AN ANTIBODY INGREDIENT CONJUGATE AND LYOPHILIZATION FOR IT |
| US20190194348A1 (en) * | 2017-11-10 | 2019-06-27 | Oregon Health & Science University | Treatment of therapy-resistant her-2 positive breast cancer |
| WO2019230645A1 (ja) | 2018-05-28 | 2019-12-05 | 第一三共株式会社 | 抗ｈｅｒ２抗体－薬物コンジュゲート投与によるｈｅｒ２変異がんの治療 |
| TWI865337B (zh) * | 2018-07-25 | 2024-12-01 | 日商第一三共股份有限公司 | 抗體-藥物結合物之有效的製造方法 |
| WO2020022475A1 (ja) | 2018-07-27 | 2020-01-30 | 第一三共株式会社 | 抗体－薬物コンジュゲートの薬物部位を認識する蛋白質 |
| US12220604B2 (en) | 2018-07-31 | 2025-02-11 | Daiichi Sankyo Company, Limited | Treatment of metastatic brain tumor by administration of an antibody-drug conjugate |
| SMT202500141T1 (it) * | 2018-09-06 | 2025-05-12 | Daiichi Sankyo Co Ltd | Coniugati farmaco-anticorpo di derivati dinucleotidici ciclici |
| DK3946464T3 (da) | 2019-03-29 | 2022-10-31 | Medimmune Ltd | Forbindelser og konjugater deraf |
| US20220387618A1 (en) | 2019-11-15 | 2022-12-08 | Seagen Inc. | Methods of treating her2 positive breast cancer with tucatinib in combination with an anti-her2 antibody-drug conjugate |
| EP4110402A1 (en) | 2020-02-25 | 2023-01-04 | Mediboston, Inc. | Camptothecin derivatives and conjugates thereof |
| KR20230042055A (ko) | 2020-07-20 | 2023-03-27 | 다이이찌 산쿄 가부시키가이샤 | 항 her2 항체-약물 콘주게이트와 her 이량체화 저해제의 조합 |
| CN115925796B (zh) * | 2020-09-30 | 2024-05-31 | 映恩生物制药（苏州）有限公司 | 一种抗肿瘤化合物及其制备方法和应用 |
| KR102247908B1 (ko) * | 2020-10-08 | 2021-05-06 | 주식회사 엠디엡투스 | Her2 압타머-항암 약물 복합체 및 이의 용도 |
| WO2022099762A1 (zh) * | 2020-11-12 | 2022-05-19 | 博瑞生物医药（苏州）股份有限公司 | 一种抗体偶联物中间体及其制备方法 |
| CN116583526B (zh) * | 2020-12-11 | 2025-09-26 | 微境生物医药科技(上海)有限公司 | 新型喜树碱衍生物、含其的组合物和其用途 |
| US20220378929A1 (en) * | 2021-02-25 | 2022-12-01 | MediBoston Limted | Anti-her2 antibody-drug conjugates and uses thereof |
| MX2023013619A (es) * | 2021-05-24 | 2023-11-30 | Remegen Co Ltd | Uso de conjugado farmaco-anticuerpo dirigido al her2 en el tratamiento del cancer de mama con expresion baja de her2. |
| US11806405B1 (en) | 2021-07-19 | 2023-11-07 | Zeno Management, Inc. | Immunoconjugates and methods |
| WO2024008102A1 (en) * | 2022-07-05 | 2024-01-11 | Wuxi Xdc (Shanghai) Co., Ltd. | Linker for conjugation |
Family Cites Families (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP3040121B2 (ja) | 1988-01-12 | 2000-05-08 | ジェネンテク，インコーポレイテッド | 増殖因子レセプターの機能を阻害することにより腫瘍細胞を処置する方法 |
| IL162181A (en) | 1988-12-28 | 2006-04-10 | Pdl Biopharma Inc | A method of producing humanized immunoglubulin, and polynucleotides encoding the same |
| ES2139598T3 (es) | 1990-07-10 | 2000-02-16 | Medical Res Council | Procedimientos para la produccion de miembros de parejas de union especifica. |
| GB9015198D0 (en) | 1990-07-10 | 1990-08-29 | Brien Caroline J O | Binding substance |
| JP3008226B2 (ja) | 1991-01-16 | 2000-02-14 | 第一製薬株式会社 | 六環性化合物 |
| CA2103059C (en) | 1991-06-14 | 2005-03-22 | Paul J. Carter | Method for making humanized antibodies |
| EP0605522B1 (en) | 1991-09-23 | 1999-06-23 | Medical Research Council | Methods for the production of humanized antibodies |
| WO1993011236A1 (en) | 1991-12-02 | 1993-06-10 | Medical Research Council | Production of anti-self antibodies from antibody segment repertoires and displayed on phage |
| JP3507073B2 (ja) | 1992-03-24 | 2004-03-15 | ケンブリッジ アンティボディー テクノロジー リミティド | 特異的結合対の成員の製造方法 |
| GB9313509D0 (en) | 1993-06-30 | 1993-08-11 | Medical Res Council | Chemisynthetic libraries |
| EP0731842A1 (en) | 1993-12-03 | 1996-09-18 | Medical Research Council | Recombinant binding proteins and peptides |
| JPH08337584A (ja) | 1995-04-10 | 1996-12-24 | Dai Ichi Seiyaku Co Ltd | 縮合六環式アミノ化合物、これを含有する医薬及びその製法 |
| TW527183B (en) | 1996-06-06 | 2003-04-11 | Daiichi Seiyaku Co | Drug complex |
| PT1071700E (pt) | 1998-04-20 | 2010-04-23 | Glycart Biotechnology Ag | Modificação por glicosilação de anticorpos para melhorar a citotoxicidade celular dependente de anticorpos |
| HK1042438A1 (zh) | 1998-10-30 | 2002-08-16 | 第一制药株式会社 | Dds化合物及其测定方法 |
| WO2000061739A1 (fr) | 1999-04-09 | 2000-10-19 | Kyowa Hakko Kogyo Co., Ltd. | Methode de regulation de l'activite d'une molecule immunologiquement fonctionnelle |
| PL203326B1 (pl) | 1999-06-25 | 2009-09-30 | Genentech Inc | Przeciwciało, kompozycja farmaceutyczna, koniugat, izolowany kwas nukleinowy, wektor, komórka gospodarza i sposób wytwarzania przeciwciała |
| KR20020012292A (ko) | 1999-06-25 | 2002-02-15 | 제넨테크, 인크. | 항-ＥｒｂＢ 항체-메이탄시노이드 결합체를 사용한 치료방법 |
| MXPA03002974A (es) | 2000-10-06 | 2004-05-05 | Kyowa Hakko Kogyo Kk | Celulas que producen composiciones de anticuerpo. |
| PH12020552271A1 (en) * | 2014-01-31 | 2022-05-02 | Daiichi Sankyo Co Ltd | Anti-her2 antibody-drug conjugate |
-
2017
- 2017-10-05 CA CA3036941A patent/CA3036941C/en active Active
- 2017-10-05 AU AU2017341000A patent/AU2017341000B2/en active Active
- 2017-10-05 KR KR1020237038566A patent/KR20230158641A/ko not_active Ceased
- 2017-10-05 BR BR112019005247A patent/BR112019005247A2/pt unknown
- 2017-10-05 WO PCT/JP2017/036215 patent/WO2018066626A1/ja not_active Ceased
- 2017-10-05 EP EP17858462.9A patent/EP3524267A4/en active Pending
- 2017-10-05 JP JP2018543951A patent/JPWO2018066626A1/ja active Pending
- 2017-10-05 CN CN201780062054.2A patent/CN109789211A/zh active Pending
- 2017-10-05 US US16/334,008 patent/US20190330368A1/en active Pending
- 2017-10-05 KR KR1020197011914A patent/KR20190066026A/ko not_active Ceased
- 2017-10-05 SG SG10201912173RA patent/SG10201912173RA/en unknown
- 2017-10-06 TW TW111125911A patent/TWI868465B/zh active
- 2017-10-06 TW TW106134472A patent/TWI827534B/zh active
-
2022
- 2022-04-15 JP JP2022067540A patent/JP2022095908A/ja active Pending
-
2024
- 2024-02-07 JP JP2024016749A patent/JP2024054226A/ja not_active Withdrawn
-
2025
- 2025-02-13 AU AU2025201016A patent/AU2025201016A1/en active Pending